Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)

NCT00565266 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2018-07-02

Study results available
· View outcomes & findings →

Summary

Typically, people with asthma are initially prescribed a low dose of inhaled corticosteroid (ICS) medication to control asthma symptoms. If a low dose of ICS is ineffective at controlling symptoms, the addition of a second controller medication is recommended. This study will examine the effectiveness of the medication tiotropium bromide combined with a low dose of ICS at maintaining asthma control in people with moderately severe asthma.

Conditions

Interventions

DRUG

tiotropium bromide

tiotropium bromide inhalation powder 18 mcg once daily

DRUG

salmeterol xinafoate

salmeterol xinafoate inhalation powder 50 mcg twice daily

DRUG

beclomethasone dipropionate

beclomethasone dipropionate 80 mcg twice daily (1xICS) or 160 mcg twice daily (2xICS)

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH
  • Milton S. Hershey Medical Center

    lead OTHER

Principal Investigators

  • Homer A. Boushey, MD · University of California, San Francisco

  • Richard J. Martin, MD · National Jewish Health

  • Elliot Israel, MD · Brigham and Women's Hospital

  • Stephen I. Wasserman, MD · University of California, San Diego

  • Mario Castro, MD · Washington University School of Medicine

  • Emily A. DiMango, MD · Columbia University

  • Stephen P. Peters, MD, PhD · Wake Forest University Health Sciences

  • Monica Kraft, MD · Duke University

  • William J. Calhoun, MD · University of Texas

  • Robert F. Lemanske, MD · University of Wisconsin, Madison

  • Reuben M. Cherniack, MD · National Jewish Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00565266 on ClinicalTrials.gov